Moreover, MaxCyte enabled predominantly homozygous knockin efficiencies in as many as 72% of subclones at the DYSF gene locus in Miyoshi myopathy patient iPSCs (Figure 2). The gene discussed is DYSF; the disease is Miyoshi myopathy.